Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia

Abstract

Background Gilteritinib is a novel FMS-like tyrosine kinase 3 inhibitor recently approved by the United States Food and Drug Administration in 2018 for relapsed or refractory acute myeloid leukemia. However, gilteritinib may be associated with underrecognized cardiotoxicities. Case presentation This case describes a patient with a history significant for hyperlipidemia who was diagnosed with relapsed acute myeloid leukemia. After four doses of gilteritinib monotherapy, she abruptly developed acute systolic heart failure with global hypokinesis and septal wall motion abnormalities. Two days after discontinuation, cardiac magnetic resonance imaging showed partial recovery of her left ventricular ejection fraction as well as myocardial edema and non-ischemic fibrosis suggestive of inflammatory cardiomyopathy. She underwent intravenous diuresis and eventually started guideline-directed heart failure therapy. Follow-up cardiac magnetic resonance imaging five months later showed improved ejection fraction with mild non-ischemic fibrosis and resolution of myocardial edema and inflammation. She later received an allogeneic stem cell transplant from a matched unrelated donor. Conclusions Gilteritinib may be associated with early cardiotoxicities, including non-ischemic cardiomyopathy and myocarditis. Cardiac magnetic resonance imaging can be an important modality to help differentiate or diagnose early cardiotoxicities associated with novel targeted therapies.

Gilteritinib (Xospata ®) in Turkey: Early Access Program Results

“…Gilteritinib-related cardiotoxicity has rarely been reported. Although the definite effect is unknown, 20 gilteritinib-related cardiotoxicity was not observed in our cases, so peripheral edema was not associated with cardiotoxicity.…”

Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy

“…Another example is fms-like receptor tyrosine kinase (Flt3), which could be an attractive target to treat AML. However, inhibitors may lead to acute cardiotoxicity ( Kim et al, 2021 ). It should be noted that Flt3 expression was found in murine cardiomyocytes, and expression in human induced pluripotent stem cell–derived cardiomyocytes was sufficient to result in mild but detectable activation of Flt3-targeted CAR T cells ( Niswander et al, 2023 ; Pfister et al, 2014 ).…”

EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring

“…However, cardiac nuclear imaging is not commonly used to monitor cardiotoxicity because it provides only limited information about cardiac structure and hemodynamics and is limited by radiation exposure ( 50 ). When the time and possibility of reversibility of cardiac insufficiency caused by TKIs are not clear, CMR can be used as an important assessment tool to identify, and diagnose early cardiac damage that may be caused by such drugs by performing baseline and periodic cardiac vascular assessments in patients receiving targeted drug therapy ( 51 ). One study ( 52 ) showed that CMR assessed a decrease in LVEF and GLS in patients treated with low-dose anthracyclines from baseline to after 6 months.…”